Related Experiment Video
Updated: Jul 2, 2025

Assays for the Degradation of Misfolded Proteins in Cells
Published on: August 28, 2016
Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome
Tanmoy Dutta1, Kavitha Sasidharan1, Ester Ciociola1
1Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.
Objective:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global health concern with no effective and specific drug treatment available. The rs2642438 minor allele in mitochondrial amidoxime-reducing component 1 (MARC1) results in an aminoacidic substitution (p.Ala165Thr) and associates with protection against MASLD. However, the mechanisms behind this protective effect are unknown. In this study, we examined the consequences of this aminoacidic substitution on protein stability and subcellular localization.
Methods:
We overexpressed the human MARC1 A165 (wild-type) or 165T (mutant) in vivo in mice and in vitro in human hepatoma cells (HepG2 and HuH-7), generated several mutants at position 165 by in situ mutagenesis and then examined protein levels. We also generated HepG2 cells stably overexpressing MARC1 A165 or 165T to test the effect of this substitution on MARC1 subcellular localization.
Results:
MARC1 165T overexpression resulted in lower protein levels than A165 both in vivo and in vitro. Similarly, any mutant at position 165 showed lower protein levels compared to the wild-type protein. We showed that the 165T mutant protein is polyubiquitinated and its degradation is accelerated through lysine-48 ubiquitin-mediated proteasomal degradation. We also showed that the 165T substitution does not affect the MARC1 subcellular localization.
Conclusions:
This study shows that alanine at position 165 in MARC1 is crucial for protein stability, and the threonine substitution at this position leads to a hypomorphic protein variant due to lower protein levels. Our result supports the notion that lowering hepatic MARC1 protein level may be a successful therapeutic strategy for treating MASLD.
Insights
The MARC1 A165T variant, linked to protection against metabolic dysfunction-associated steatotic liver disease (MASLD), shows reduced protein stability and accelerated degradation. Lowering hepatic MARC1 levels may offer a therapeutic strategy for MASLD.
Area of Science:
- Biochemistry
- Genetics
- Hepatology
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health issue lacking specific treatments.
- A genetic variant (rs2642438 minor allele) in the MARC1 gene, resulting in an Ala165Thr substitution, is associated with protection against MASLD, but the underlying mechanisms are unclear.
Purpose of the Study:
- To investigate the impact of the MARC1 p.Ala165Thr substitution on protein stability and subcellular localization.
- To elucidate the molecular mechanisms behind the protective effect of the MARC1 variant against MASLD.
Main Methods:
- Overexpression of wild-type (A165) and mutant (165T) MARC1 in mouse models and human hepatoma cell lines (HepG2, HuH-7).
- Site-directed mutagenesis to generate various mutants at position 165.
- Assessment of protein levels, ubiquitination status, and subcellular localization.
Main Results:
- The MARC1 165T mutant exhibited significantly lower protein levels compared to the wild-type A165 form, both in vivo and in vitro.
- Mutations at position 165 generally led to reduced protein stability.
- The 165T mutant protein was found to be polyubiquitinated and degraded via the ubiquitin-proteasome pathway (lysine-48 linkage).
- The substitution at position 165 did not alter the subcellular localization of MARC1.
Conclusions:
- Alanine at position 165 of MARC1 is critical for protein stability.
- The threonine substitution (p.Ala165Thr) results in a hypomorphic MARC1 variant with decreased protein levels.
- Reduced hepatic MARC1 protein levels may represent a viable therapeutic approach for managing MASLD.
More Related Videos
Related Concept Videos
Translocation of Proteins into the Mitochondria
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Mitochondrial Precursor Proteins
Most of the mitochondrial...
Mitochondrial Protein Sorting
Most of these mitochondrial proteins are encoded by the nucleus and imported to the mitochondria as unfolded or loosely folded precursors. Mitochondrial precursors...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Export of Misfolded Proteins out of the ER

